- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02028871
Intranasal Insulin for Weight Management During Smoking Cessation
December 7, 2018 updated by: Ajna Hamidovic
This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- UNM College of Pharmacy
-
Albuquerque, New Mexico, United States
- UNM College of Pharmacy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- smokers (>10 cig/day) for the past 1 year
- normosmic olfactory function
Exclusion Criteria:
- previous/current use of insulin
- current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder
- current pregnancy (or lactation)
- lifetime history of endocrine disease
- excessive alcohol use (>25 standard units of alcohol/week)
- current use of illicit drugs
- current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic agent
- local infections, inflammation, structural abnormalities, or other nasal pathology
- current use of any medications administered intranasally, including intranasal steroids
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Intranasal Insulin First
Intranasal Insulin First, Placebo Second
|
|
|
Placebo Comparator: Placebo First
Placebo First, Intranasal Insulin Second
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Amount Eaten in Taste Test
Time Frame: 90 minutes
|
90 minutes
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nicotine Cravings Measured by Questionnaire of Smoking Urges
Time Frame: 210 minutes
|
Range: 7-70.
Higher scores mean worse outcome
|
210 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ajna Hamidovic, PharmD, University of New Mexico
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2014
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
May 1, 2016
Study Registration Dates
First Submitted
January 3, 2014
First Submitted That Met QC Criteria
January 3, 2014
First Posted (Estimate)
January 7, 2014
Study Record Updates
Last Update Posted (Actual)
December 10, 2018
Last Update Submitted That Met QC Criteria
December 7, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 120700
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Abstinence Syndrome
-
Ajna HamidovicCompletedTobacco Abstinence SyndromeUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco AbstinenceUnited States
-
University of Colorado, DenverUniversity of OklahomaRecruitingSmoking Cessation | Tobacco | Quitting Smoking | Tobacco Abstinence | Smoking (Tobacco) Addiction | Smoking ( Cigarette)United States
-
Mayo ClinicCompleted
-
Yale UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Tobacco AbstinenceUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine Withdrawal | Tobacco AbstinenceUnited States
-
University of SalernoNot yet recruitingSmoking Cessation | Smoking Behaviors | Smoking Dependence | Smoking Abstinence | Smoking Cessation Intervention | Smoking (Tobacco) Addiction | Smoking E-cigarette | Smoking Addiction | Smoking ( Cigarette)
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institutes of Health (NIH); University...RecruitingSmoking Cessation | Human Immunodeficiency Virus (HIV) | Tobacco | Tobacco Abstinence | Cancer Prevention | Smoking Cessation; Tobacco Dependence | Tobacco Dependence Caused by CigarettesUnited States
-
IVI BilbaoInstituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
Alternatives For GirlsRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States